Last update 12 Dec 2024

TQB-2618

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
TQB 2618, TQB2618
Target
Mechanism
TIM3 inhibitors(Hepatitis A virus cellular receptor 2 inhibitors)
Inactive Indication-
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Esophageal Squamous Cell CarcinomaPhase 2
CN
26 May 2023
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
CN
23 May 2023
Squamous cell carcinoma, metastaticPhase 2
CN
23 May 2023
Nasopharyngeal CarcinomaPhase 2
CN
27 Oct 2022
Recurrent LymphomaPhase 2
CN
09 Jun 2022
Refractory LymphomaPhase 2
CN
09 Jun 2022
Advanced Malignant Solid NeoplasmPhase 2
CN
28 Apr 2022
Squamous cell carcinoma of head and neck metastaticPhase 1
CN
14 Mar 2024
Colorectal CancerPhase 1
CN
22 Dec 2023
Advanced Hepatocellular CarcinomaPhase 1
CN
15 Aug 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
WCLC2024
ManualManual
Phase 1
93
(jsunglbcfr) = kvigtydmtb bhnkkvpzeq (wpnzhplplc )
Positive
10 Sep 2024
(jsunglbcfr) = ztcvdquhwh bhnkkvpzeq (wpnzhplplc )
Phase 1
21
TQB2618 60Penpulimabulimab 200mg
rcklrjruqk(tglgemywmx) = 17 (81%) patients experienced treatment-related adverse events (TRAEs), 5 (23.8%) of whom experienced grade 3 or above TRAEs. The most frequent TRAEs (≥15%) were platelet count decreased (23.8%), anemia (23.8%), alanine aminotransferase increased (19%) and Aspartate aminotransferase increased (19%). The most common grade 3 or above TRAEs were anemia (9.5%) and white blood count decreased (9.5%). jlssfzorcs (zjxngfdiqy )
Positive
14 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free